Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Enanta Pharmaceuticals (ENTA) Delivers Fiscal 2026 Results with Wider Loss and Extended Cash Runway

Enanta Pharmaceuticals (ENTA) Delivers Fiscal 2026 Results with Wider Loss and Extended Cash Runway

Key Takeaways

  • Enanta reported a fiscal fourth-quarter 2026 net loss of $23.7 million, or $0.81 per share, versus a loss of $18.7 million, or $0.87 per share, a year earlier.
  • Quarterly revenue fell to $12.9 million from $15.1 million, below the FactSet consensus estimate of roughly $14.6 million.
  • Full-year revenue declined to $63.0 million from $65.3 million, with a fiscal 2026 net loss of $68.2 million, or $2.35 per share.
  • Research and development (R&D) spending rose to $26.1 million in the quarter, up from $23.8 million a year earlier, as the company advanced its immunology programs.
  • Enanta reduced its workforce by roughly one-third as part of cost actions, while management reiterated a cash runway expected to fund operations into fiscal 2029.

Placing the Earnings in Context

Enanta Pharmaceuticals is a clinical-stage biotechnology company whose only commercial revenue currently comes from royalties tied to AbbVie's hepatitis C virus (HCV) treatment MAVYRET/MAVIRET. Those royalties have been shrinking steadily, making quarterly results an important gauge of how long the company's cash can support its drug pipeline. Investors are watching closely because Enanta is pivoting toward immunology and respiratory syncytial virus (RSV) programs that have yet to generate product sales. The fiscal fourth quarter and full-year 2026 results therefore matter less for current profitability and more for the signals they send about cost discipline, cash runway, and the timing of upcoming clinical catalysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What the Numbers Actually Show

Enanta reported fiscal fourth-quarter 2026 revenue of $12.9 million, down from $15.1 million in the year-ago period and below the FactSet consensus estimate of about $14.6 million. Revenue consists almost entirely of royalties from AbbVie's HCV product sales, which continue to decline.

The company posted a net loss of $23.7 million, or $0.81 per share, compared with a loss of $18.7 million, or $0.87 per share, a year earlier. The loss was wider than the roughly $0.72-per-share consensus loss expected by analysts. Research and development expenses increased to $26.1 million from $23.8 million, reflecting investment in the immunology pipeline.

For the full fiscal year 2026, revenue totaled $63.0 million, down from $65.3 million in fiscal 2025, while the net loss widened to $68.2 million, or $2.35 per share. Enanta also disclosed a workforce reduction of approximately one-third in connection with its cost actions. Management expects its cash, cash equivalents, and marketable securities, together with retained royalty revenue, to fund operations into fiscal 2029.

Market Reaction and Sentiment

Enanta shares entered the report under significant pressure, having lost roughly 30% of their value since the start of 2026 while the broader S&P 500 advanced. The stock has also declined more than 18% over the trailing three months, reflecting investor concern about fading HCV royalties and the absence of near-term product revenue. The wider-than-expected quarterly loss and the revenue shortfall are unlikely to improve that sentiment in the short term. However, the company's pipeline readouts, rather than the income statement, have historically driven the stock's most meaningful moves.

Forward Outlook and What to Watch

The near-term story for Enanta centers on execution across its pipeline rather than quarterly earnings. Management said it expects to complete dosing in the Phase 1 trial of EDP-978, an oral KIT inhibitor being developed for chronic urticaria and other mast cell-driven diseases, by the end of 2026, with data now planned for the first quarter of 2027.

On the virology side, investors will watch for the start of the registrational RESOLVE study of zelicapavir in high-risk adults with RSV, as well as pediatric Phase 2b (LOTUS) data anticipated in 2027. The company is also progressing EPS-3903, an oral STAT6 inhibitor, toward an investigational new drug (IND) filing in the second half of 2026. Financially, the key monitor is the trajectory of AbbVie HCV royalties, which remain the company's only source of revenue.

Integrating AI Tools into My Research

In my own workflow I frequently turn to Tickeron’s AI Screener when evaluating names like this one. It helps me quickly filter for technical patterns, performance metrics, and industry comparisons that complement the fundamental story. The tool is straightforward to use and gives me a structured view alongside the clinical and cash-flow details I track manually.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ENTA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ENTA in +13.79% Uptrend, advancing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ENTA advanced for three days, in 207 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ENTA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

ENTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 52 cases where ENTA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ENTA as a result. In 62 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for ENTA turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 48 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for ENTA entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.170) is normal, around the industry mean (3.592). P/E Ratio (-4.545) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.550) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (5.285) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. ENTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of drugs and other pharmaceuticals products

Industry Biotechnology

Industry
Biotechnology
Address
4 Kingsbury Avenue
Phone
+1 617 607-0800
Employees
120
Web
https://www.enanta.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.